ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
2seventy bio Inc

2seventy bio Inc (TSVT)

4.79
0.22
(4.81%)
At close: July 26 4:00PM
4.81
0.02
( 0.42% )
After Hours: 6:40PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.81
Bid
4.43
Ask
4.94
Volume
337,211
4.53 Day's Range 4.825
1.535 52 Week Range 10.02
Market Cap
Previous Close
4.57
Open
4.69
Last Trade Time
Financial Volume
$ 1,574,294
VWAP
4.6686
Average Volume (3m)
511,576
Shares Outstanding
51,405,419
Dividend Yield
-
PE Ratio
-1.13
Earnings Per Share (EPS)
-4.23
Revenue
100.39M
Net Profit
-217.57M

About 2seventy bio Inc

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TSVT. The last closing price for 2seventy bio was $4.57. Over the last year, 2seventy bio shares have traded in a share price range of $ 1.535 to $ 10.02.

2seventy bio currently has 51,405,419 shares outstanding. The market capitalization of 2seventy bio is $234.92 million. 2seventy bio has a price to earnings ratio (PE ratio) of -1.13.

TSVT Latest News

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by...

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.347.60626398214.474.8254.312579384.51711229CS
41.0126.57894736843.85.0353.75059254.26629071CS
12-0.12-2.434077079114.935.12993.545115764.25168308CS
261.4844.44444444443.336.42.8959930474.78130955CS
52-5.07-51.31578947379.8810.021.53513647224.14158086CS
156-21.32-81.59203980126.1344.341.5358632978.43437849CS
260-21.32-81.59203980126.1344.341.5358632978.43437849CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.55M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.51M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
258.51k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.05M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.68M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.89M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
714.54k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.01M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
404.94M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.51M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.16M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.42M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.64M

TSVT Discussion

View Posts
Monksdream Monksdream 3 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 4 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 5 months ago
TSVT 10Q due March 5
👍️0
molee molee 6 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1 💩 1 🤡 1
johnhancoque johnhancoque 8 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 9 months ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0